JPET Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on November 20, 2007; DOI: 10.1124/jpet.107.131896


0022-3565/08/3242-475-483$20.00
JPET 324:475-483, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.131896v1
324/2/475    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Muñoz-Luque, J.
Right arrow Articles by Jiménez, W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muñoz-Luque, J.
Right arrow Articles by Jiménez, W.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats

Javier Muñoz-Luque, Josefa Ros, Guillermo Fernández-Varo, Sònia Tugues, Manuel Morales-Ruiz, Carlos E. Alvarez, Scott L. Friedman, Vicente Arroyo, and Wladimiro Jiménez

Biochemistry and Molecular Genetics Service (J.M.-L., J.R., G.F.-V., S.T., M.M.-R., W.J.), Department of Physiology I (W.J.) and Liver Unit (V.A.), Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; and Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York (C.E.A., S.L.F.)

Two cannabinoid (CB) receptor subtypes, CB1 and CB2, have been cloned and characterized. Among other activities, receptor activation by cannabinoid ligands may result in pro- or antifibrogenic effects depending on their interaction with CB1 or CB2, respectively. In the current study, we investigated whether selective activation of hepatic CB2 modifies collagen abundance in cirrhotic rats with ascites. mRNA and protein expression of CB receptors in the liver of control and cirrhotic rats was assessed by reverse transcription-polymerase chain reaction, Western blot, and immunohistochemistry. The effect of chronically activating the CB2 receptor was investigated in cirrhotic rats with ascites treated daily (9 days) with the CB2 receptor-selective agonist 3-(1,1-dimethylbutyl)-1-deoxy-{Delta}8-tetrahydrocannabinol (JWH-133). At the end of treatment, mean arterial pressure and portal pressure were measured, and liver samples were obtained to evaluate infiltrate of mononuclear cells, hepatic apoptosis, {alpha}-smooth muscle actin (SMA) expression, collagen content, and matrix metalloproteinase (MMP)-2 abundance in all animals. JWH-133 improved arterial pressure, decreased the inflammatory infiltrate, reduced the number of activated stellate cells, increased apoptosis in nonparenchymal cells located in the margin of the septa, and decreased fibrosis compared with cirrhotic rats treated with vehicle. This was associated with decreased {alpha}-SMA and collagen I and increased MMP-2 in the hepatic tissue of cirrhotic rats treated with the CB2 agonist compared with untreated cirrhotic animals. Therefore, selective activation of hepatic CB2 receptors significantly reduces hepatic collagen content in rats with pre-existing cirrhosis, thus raising the possibility of using selective CB2 agonists for the treatment of hepatic fibrosis in human cirrhosis.


Received September 19, 2007; accepted November 19, 2007.

Address correspondence to: Dr. Wladimiro Jiménez, Servicio de Bioquímica y Genética Molecular, Hospital Clinic Universitari, Villarroel 170, Barcelona 08036, Spain. E-mail: wjimenez{at}clinic.ub.es







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.